Antibiotic treatment increases the severity of asthma in young mice
“We administered antibiotics to mice of different ages to determine if there was a link between the makeup of the microbial community in the gut and the extent of experimentally induced allergic asthma,” said Dr. Brett Finlay, Professor at the Michael Smith Laboratories at the University of British Columbia, Canada. “Treatment of young mice with the antibiotic vancomycin reduced the diversity of microbes in the gut, significantly altered the composition of the bacterial population, and increased the susceptibility of young animals to experimentally induced asthma.”
Many studies have suggested that the colonization of the gut early in life plays a substantial role in shaping the development of the immune system. More than 100 trillion bacteria, including more than 1000 bacterial species, colonize the human gut. If the balance of the microbial community in the gut is disrupted, the ability of the body to resist the onset of disease may be compromised.
Dr. Finlay remarked: “Although the precise link between the immune responses in the gut and lung remain unclear, we think that vancomycin selects for a community of microbes in the gut that somehow disrupts the inflammatory and regulatory immune responses at the two different sites. In mice, the restructuring of the intestinal microbial population during infancy after antibiotic treatment is enough to lead to exacerbated asthma.”
The scientists used genome sequencing of the microbial population to reveal the diversity of the microbial community. The severity of asthma was assessed by different molecular assays and direct examination of lung tissue.
Said Finlay: “Our results confirm that the early months of life are a crucial time in which the gut microbial community may influence key immunological events that alter the sensitivity of the body’s immune system to the response to allergens.”
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.